ALEMBIC LTD.

Alembic Ltd has announced that its Board of Directors will convene on November 6, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. Following the declaration of these results, the trading window for dealing in the company's securities, which was closed from October 1, 2026, will reopen 48 hours after the announcement.

Alembic Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1st, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30th, 2026. The specific date for the Board Meeting to approve these financial results will be communicated to the exchanges in due course. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Alembic Limited conducted its 119th Annual General Meeting (AGM) on August 11, 2026, via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The meeting, attended by all directors, focused on adopting the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. Key agenda items included the declaration of dividend for FY 2025-26, the re-appointment of a director retiring by rotation, payment of commission to a Non-Executive Director, and ratification of remuneration for Cost Auditors. Shareholders had the opportunity to vote electronically, and the results were to be declared by August 13, 2026. The meeting concluded with 76 members in attendance.

Alembic Ltd announced its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting held on August 11, 2026. The filing includes the unaudited financial results and a limited review report from the statutory auditors. The company provided details on segment-wise consolidated revenue and results for its Active Pharmaceutical Ingredients and Real Estate businesses.

Alembic Ltd's consolidated Q1 FY27 (quarter ended 30 June 2026) net profit — including its share of associate Alembic Pharmaceuticals' profit — was ₹64.89 Cr, up 5.3% YoY from ₹61.64 Cr but down 3.3% QoQ from ₹67.13 Cr; EPS was ₹2.53 versus ₹2.40 a year ago. Consolidated revenue from operations fell 2.0% YoY to ₹48.74 Cr and 18.8% QoQ from ₹60.04 Cr, the QoQ drop reflecting lumpy real-estate revenue recognition rather than a change in run-rate. Strip out the associate contribution and the underlying picture is weaker: Alembic Ltd's own pre-associate profit before tax was ₹17.34 Cr, down 12.3% YoY, and its own post-tax profit (before the associate share) was ₹15.70 Cr versus ₹17.80 Cr a year ago — core operating margin (own PBT/revenue) compressed to 35.6% from 39.8% YoY. Employee costs rose 33.6% YoY (₹10.46 Cr vs ₹7.83 Cr) and other expenses rose 38.9% YoY, both outpacing the revenue decline and driving that margin compression even as consolidated total expenses grew 11.4% YoY. The headline PAT growth was driven almost entirely by Alembic's stake in Alembic Pharmaceuticals: the associate profit share booked by Alembic Ltd rose 12.2% YoY to ₹49.19 Cr and now accounts for 76% of consolidated PAT, up from 71% a year ago. That tracks with Alembic Pharmaceuticals' own Q1 FY27 print reported separately on 4 August 2026 — consolidated net profit of ₹173 Cr, up 12.1% YoY on 26% revenue growth — where management raised FY27 revenue guidance to mid-teens from low-double-digit; that guidance belongs to the associate, not to Alembic Ltd, which has no guidance of its own on record (guidanceSource: none) and no analyst coverage or street estimates found for the holding entity itself. At the segment level, both of Alembic Ltd's own businesses lost ground YoY: the API segment result fell 39.2% YoY to ₹1.66 Cr (though it recovered from a ₹1.17 Cr loss in Q4 FY26), and the Real Estate segment result fell 12.3% YoY to ₹13.98 Cr (down 33.3% QoQ). Standalone PAT (Alembic Ltd excluding its Alembic City subsidiary) was ₹14.68 Cr, down 14.2% YoY from ₹17.12 Cr, with EPS of ₹0.57 versus ₹0.67. No separate management commentary or press release accompanied this filing beyond the standard board-outcome letter to the exchanges, and the auditors carried forward an unchanged emphasis-of-matter on the ₹20.52 Cr electricity-duty dispute with Gujarat authorities (₹35 Cr already deposited with the Supreme Court), with no new provision this quarter. Heading into Q2 FY27, Alembic Ltd's reported profit trajectory now leans more on Alembic Pharmaceuticals' growth than on its own API and real-estate operations, both of which softened this quarter.

Alembic Ltd has announced that its Board of Directors will convene on August 11, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026. The trading window for dealing in the company's securities, which was closed from July 1, 2026, will reopen 48 hours after the declaration of these financial results. This meeting is a routine procedural step for the company to finalize its quarterly financial performance.

Alembic Ltd has announced its 119th Annual General Meeting (AGM) scheduled for August 11, 2026. The company is distributing the Annual Report for FY 2025-26 to shareholders. For those whose email addresses are not registered, a physical letter with a web-link to access the report online has been sent. The report includes the AGM notice. Key dates for dividend and e-voting have also been provided. Shareholders are reminded to update their KYC details if necessary.

Alembic Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, and contact information for queries. It outlines the company's business activities, primarily in Real Estate (79.91% turnover) and API Manufacturing (20.09% turnover). The report also covers operational locations, markets served (including 0.54% exports), customer types, employee details (198 employees, 131 workers), and gender representation. Notably, it includes turnover rates for permanent employees and workers over the past three financial years.

Alembic Ltd has announced Tuesday, August 4, 2026, as the Record Date for determining shareholder entitlement to receive dividends for the financial year ended March 31, 2026. The dividend payment will be processed according to the Companies Act, 2013, following its approval at the Annual General Meeting scheduled for August 11, 2026. This intimation is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alembic Limited has filed its 119th Annual Report for the financial year ended March 31, 2026, as per SEBI regulations. The report includes standalone and consolidated financial statements, board and auditor reports, and corporate governance details. The company also announced its 119th Annual General Meeting (AGM) scheduled for August 11, 2026, to be held via Video Conferencing. Key agenda items include the adoption of financial statements, declaration of dividend for FY25-26, and the re-appointment of a director. The report also highlights the company's real estate venture, Alembic City, featuring various residential options in Vadodara.